Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Thomas Pitts

Neurology New York, NY Medical Doctor

NPI 1750624656 CMS profile 2787544

281 Broadway Fl 2, New York, NY 10007

Open in the dashboard

General payments

$211,241

518 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Thomas Pitts of New York, NY is reported in the CMS Open Payments database as having received $211,241 across 518 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $2,303 2
2022 General $29,338 78
2021 General $17,322 100
2020 General $59,665 134
2019 General $102,612 204

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Pitts
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Thomas Pitts were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Thomas Pitts Neurology median Middle half National median
2019 $102,612 $474 $118–$2,177 $163
2020 $59,665 $367 $82–$2,309 $114
2021 $17,322 $438 $104–$2,547 $132
2022 $29,338 $442 $103–$2,388 $149
2023 $2,303 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Alexion Pharmaceuticals, Inc. $200,216 355 payments
  2. Catalyst Pharmaceuticals, Inc. $7,315 14 payments
  3. Amgen Inc. $663 21 payments
  4. Biohaven Pharmaceuticals, Inc. $387 13 payments
  5. Horizon Therapeutics plc $351 9 payments
  6. Teva Pharmaceuticals USA, Inc. $305 11 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $274 19 payments
  8. AbbVie, Inc. $243 10 payments
  9. Novartis Pharmaceuticals Corporation $240 13 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $227 7 payments
  11. Other $1,020 46 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $160,554 106 payments
  2. Travel and Lodging $28,590 125 payments
  3. Food and Beverage $8,340 274 payments
  4. Honoraria $7,300 7 payments
  5. Consulting Fee $6,358 5 payments
  6. Education $99 1 payment
Products named General payments · program years 2019–2023
  1. Soliris Immunology $158,741 293 payments
  2. ULTOMIRIS $21,829 28 payments
  3. FIRDAPSE $7,315 14 payments
  4. SOLIRIS Rare Disease $3,427 6 payments
  5. AIMOVIG $748 25 payments
  6. NURTEC ODT $614 20 payments
  7. UPLIZNA $268 5 payments
  8. RELISTOR $230 16 payments
  9. AUSTEDO $206 10 payments
  10. UBRELVY $171 7 payments
  11. Other $1,610 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$8,099

Medicare's payments for the services billed

Medicare patients

69

Average age 74

Services billed

86

27 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 46%
Chronic kidney disease 42%
Depression 39%
Diabetes 38%
Heart failure 35%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

518 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record